TITLE

Mylotarg

PUB. DATE
August 2010
SOURCE
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the announcement of Pfizer Inc. that it will cease the marketing of Mylotarg for it increases death date in patients suffering from leukemia in the U.S.
ACCESSION #
52817411

 

Related Articles

  • Pfizer loses bid to force journals to reveal peer review comments. Dyer, Clare // BMJ: British Medical Journal (International Edition);4/5/2008, Vol. 336 Issue 7647, p743 

    The article reports on a decision of a U.S. federal judge in Illinois to reject a bid from the pharmaceutical firm Pfizer to force two leading medical journals to hand over confidential documents relating to peer reviews which were conducted on studies of the firm's drugs Bextra and Celebrex....

  • Orally inhaled insulin for type 1 and type 2 diabetes.  // Cortlandt Forum;Aug2006, Vol. 19 Issue 8, p23 

    The article provides information about Exubera, the orally inhaled insulin, developed by Pfizer Inc. in the U.S. The drug is indicated for use by patients with type 1 and type 2 diabetes. Exubera is a dry powder form of human insulin that is self-administered using its inhaler. Adverse reactions...

  • More caution advised in using impotence drug Viagra.  // Mayo Clinic Health Letter;Mar1999, Vol. 17 Issue 3, p4 

    Reports that the United States Food and Drug Administration and Pfizer Inc. has issued a warning to physicians and patients to be more cautious in using the impotence drug Viagra. Number of men who have died shortly after taking the drug since the introduction of the drug in April 1998; Content...

  • Pfizer Suspends Arthritis Drug.  // Pharmaceutical Executive;Jul2010, Vol. 30 Issue 7, p13 

    The article reports on the decision of pharmaceutical company Pfizer Inc. to cease production of their osteoarthritis drug tenuzemab, after reports that the treatment was exacerbating the symptoms of patients.

  • Ziprasidone hydrochloride: labelling clarifications.  // WHO Drug Information;2002, Vol. 16 Issue 1, p23 

    Reports on a letter issued by Pfizer Inc. to inform health care professionals about clarifications to the labeling of its ziprasidone HCl capsules (Geodon). Drugs with which ziprasidone should not be given; Contraindication with other drugs; Avoidance of ziprasidone in patients with congenital...

  • Risk of intraocular hypertension with pegaptanib.  // Reactions Weekly;10/20/2012, Issue 1424, p4 

    The article deals with the warning issued by Pfizer to healthcare professionals about the risk of intraocular pressure associated with intravitreal injection of an excess volume of pegaptanib.

  • DEATH BY PRESCRIPTION. Rothschild, Matthew // Progressive;Jun86, Vol. 50 Issue 6, p18 

    Reports on the fatal and non-fatal adverse reaction to Feldene, a drug for the treatment of arthritis developed by Pfizer Corp. Total number of Feldene victims; Illegal advertising committed by Pfizer in promoting Feldene. INSETS: Banging the Drums.;'Keeping the Public Well Informed'..

  • Sitaxentan voluntarily withdrawn worldwide.  // Reactions Weekly;12/18/2010, Issue 1332, p2 

    The article reports on the voluntary withdrawal of sitaxentan by Pfizer in December 2010 due to possible life-threatening risk of liver injury.

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Jan2005, Vol. 4 Issue 1, p3 

    The article reports global developments related to the pharmaceutical industry. Continued controversies have prompted the U.S. Food and Drug Administration to implement extensive structural changes in order to avoid another scandal like the one experienced after Merck and Co. Inc.'s Vioxx was...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics